17␣-Hydroxylase (CYP17) expression in propagated theca cells isolated from the ovaries of women with polycystic ovary syndrome (PCOS) is persistently elevated, compared with theca cells isolated from normal ovaries. To investigate the mechanism for increased CYP17 messenger RNA accumulation in PCOS theca cells, we examined CYP17 and steroidogenic acute regulatory protein (StAR) promoter activities in normal and PCOS theca cells. Conditions were established to transiently transfect human theca cells with reporter gene constructs containing 5Ј truncations of the human CYP17 and StAR promoters. Cotransfection of a steroidogenic factor-1 expression plasmid was found to be required for detection of basal and forskolinstimulated CYP17 promoter activity but not for StAR promoter activity. However, cotransfection with a steroidogenic factor-1 expression plasmid augmented both basal and forskolin-stimulated StAR promoter activity. CYP17 reporter activity was compared in theca cells isolated from normal and PCOS patients. Basal and forskolinstimulated CYP17 promoter activity was 4-fold greater in PCOS cells than in theca cells isolated from normal ovaries. In contrast, StAR promoter activity, and the activity of a reporter construct containing three copies of a cAMP response element (3xCRE), were similar in normal and PCOS theca cells. The results of these studies document: 1) that basal and cAMP-dependent CYP17 gene transcription is increased in PCOS theca cells; 2) that there is differential regulation of promoters of genes required for steroidogenesis in PCOS theca cells; and 3) that passaged normal and PCOS theca cells provide a model system for studying tissue-specific regulation of genes encoding steroidogenic enzymes and identifying the molecular mechanisms involved in increased androgen production in PCOS. (J Clin Endocrinol
promoter activity. CYP17 reporter activity was compared in theca cells isolated from normal and PCOS patients. Basal and forskolinstimulated CYP17 promoter activity was 4-fold greater in PCOS cells than in theca cells isolated from normal ovaries. In contrast, StAR promoter activity, and the activity of a reporter construct containing three copies of a cAMP response element (3xCRE), were similar in normal and PCOS theca cells. The results of these studies document: 1) that basal and cAMP-dependent CYP17 gene transcription is increased in PCOS theca cells; 2) that there is differential regulation of promoters of genes required for steroidogenesis in PCOS theca cells; and 3) that passaged normal and PCOS theca cells provide a model system for studying tissue-specific regulation of genes encoding steroidogenic enzymes and identifying the molecular mechanisms involved in increased androgen production in PCOS. (J Clin Endocrinol Metab 85: 2304 -2311, 2000) P OLYCYSTIC OVARY syndrome (PCOS) is recognized to be the most common cause of infertility in reproductive-age women (1) . Reproductive and endocrine abnormalities in PCOS include increased ovarian androgen production, ovarian cysts, irregular menstrual cycles, infertility, and hirsutism or virilism of various degrees (2) (3) (4) . There are convincing data from in vivo and in vitro studies to support the concept that excess androgen production in PCOS results from an abnormality in ovarian steroid production (5-9). Gilling-Smith et al. (6) reported that androgen production is inhibited after complete GnRH suppression of pituitary LH production in patients with PCOS. Gilling-Smith et al. (10) and Nestler et al. (8) also demonstrated that androgen production per cell is increased in PCOS theca cells in primary culture. However, the molecular and cellular mechanisms underlying excessive ovarian androgen production associated with PCOS remain to be elucidated (11) (12) (13) .
In the human ovarian follicle, the androgen-secreting theca cells express the 17␣-hydroxylase (CYP17) gene that encodes a cytochrome P450 with 17␣-hydroxylase and C17, 20 lyase activities, which are necessary for the conversion of pregnenolone to 17␣-hydroxypregnenolone and dehydroepiandrosterone and for the conversion of progesterone to 17␣-hydroxyprogesterone (5, 14, 15) . These represent obligatory and key steps involved in the synthesis of androgens. Theca cells also express steroidogenic acute regulatory protein (StAR), which promotes the translocation of cholesterol to the inner mitochondrial membrane (16) , as well as cytochrome P450 cholesterol side chain cleavage enzyme (CYP11A) and 3␤-hydroxysteroid dehydrogenase (3␤-HSD), each of which is required for androgen biosynthesis (17) .
Although a number of theories have been proposed to explain the etiology of excess androgen production by PCOS ovaries, few studies have focused on the regulation of steroidogenic enzyme expression in isolated theca interna cells. We recently reported conditions to examine the regulation of androgen production at the metabolic and molecular level using normal and PCOS theca interna cells isolated from size-matched follicles and propagated for multiple population doublings (5, 18) . Using these conditions, we established that increased androgen production is a stable phenotype of PCOS theca cells that not only results from preferentially increased CYP17 expression but involves the up-regulation of other steroidogenic enzymes, including CYP11A, 3␤-HSD, and 17␤-HSD (5). These studies also revealed increased basal and cAMP-stimulated steady-state CYP17 and CYP11A messenger RNA (mRNA) levels in PCOS theca cells, as compared with normal cells. In marked contrast, basal and forskolinstimulated StAR mRNA accumulation were similar in normal and PCOS theca cells, suggesting that there are selective abnormalities in the expression of the steroidogenic machinery in PCOS theca cells.
To our knowledge, no one has defined the promoter elements required for CYP17 or StAR gene expression in human theca cells. The CYP17 gene has been shown to be regulated by cAMP in a variety of steroidogenic tissues and species, and it involves several different cis-regulatory elements and trans-acting factors (19 -23) . Examination of the cis-regulatory elements involved in basal and cAMP-stimulated CYP17 gene expression has revealed distinct tissue-and speciesspecific regulation of the gene (see Refs. 30 and 32). In contrast, StAR gene expression, in a variety of steroidogenic tissues and species, is regulated by similar cis-regulatory elements (24, 25) . The transcription factor steroidogenic factor-1 (SF-1) has been identified to be a common regulator involved in the expression of CYP17 and StAR in adrenocortical and gonadal tissues (26 -28) . SF-1 is expressed in theca and granulosa cells of the mouse (26) , rat (29) , and human (30) ovary. In the human ovary, SF-1 expression is first observed in theca cells of the preantral follicle, preceding CYP17 expression, and it increases throughout follicular development (30) . An examination of the 5Ј flanking sequence of the human CYP17 gene reveals that there are multiple copies of the consensus SF-1 binding motif (27) . The human StAR promoter has three functional SF-1 response elements involved in basal and cAMP-responsiveness (31, 32) .
Although we have reported that steady-state CYP17 mRNA levels are increased in PCOS theca cells, we did not determine whether this increase results from altered transcriptional regulation of the CYP17 gene. In this report, we have begun to examine the molecular mechanisms involved in the differential regulation of CYP17 and StAR gene transcription in normal and PCOS theca cells. Here we established conditions to transiently transfect human theca cells, with reporter gene constructs containing 5Ј truncations of the human CYP17 and StAR promoters. Transient transfection assays were then performed in normal and PCOS theca cells to determine whether differences in CYP17 and StAR mRNA accumulation could be explained by differences in transcriptional activation.
Subjects and Methods

Theca cell isolation and propagation
Human theca interna tissue was obtained from follicles of women undergoing hysterectomy, under a protocol approved by the Institutional Review Board of the Pennsylvania State University College of Medicine. Individual follicles were dissected away from ovarian stroma. The isolated follicles were size-selected for diameters ranging from 3-5 mm so that theca cells derived from follicles of similar size from normal and PCOS subjects could be compared. The dissected follicles were placed into serum-containing medium and bisected. Under a dissecting microscope, the theca interna was stripped from the follicle wall, and the granulosa cells were removed with a platinum loop. The cleaned theca shells were dispersed with 0.05% collagenase I, 0.05% collagenase IA, and 0.01% deoxyribonuclease in medium containing 10% FBS (33) . Dispersed cells were placed in culture dishes that had been precoated with fibronectin by incubation at 37 C with culture medium containing 5 g/mL human fibronectin. The growth medium used was a 1:1 mixture of Dulbecco's Eagles Medium and Hams F-12 medium containing 10% FBS, 10% horse serum, 2% UltroSer G, 20 nmol/L insulin, 20 nmol/L selenium, and 1 mol/L vitamin E and antibiotics (33) . From each follicle, 12 35-mm dishes of primary theca interna cells were grown until confluent, removed from the dish with neutral protease (pronase-E; protease type XXIV, Sigma, St. Louis, MO) in DME-F12 (1:1), frozen, and stored in liquid nitrogen (1 35-mm dish per vial) in culture medium that contained 20% FBS and 10% dimethylsulfoxide (33) . In all experiments, cells were thawed and propagated in the growth medium described above. To obtain successive passages of normal and PCOS theca cells, cells were thawed, propagated, and frozen at consecutive passages. The cells were grown in 5% O 2 , 90% N2, and 5% CO 2 . Reduced oxygen tension and supplemental antioxidants (vitamin E and selenium) were employed to prevent oxidative damage.
The PCOS and normal ovarian tissue came from age-matched women, 38 -40 yr old. The diagnosis of PCOS was made according to established guidelines (34) , including hyperandrogenemia, oligoovulation and the exclusion of 21-hydroxylase deficiency, Cushing's syndrome, and hyperprolactinemia. All of the PCOS theca cell preparations studied came from ovaries of women with fewer than six menses per year and elevated serum total testosterone or bioavailable testosterone levels, as we previously described (5, 11) . Each of the PCOS ovaries contained multiple subcortical follicles of less than 10 mm in diameter. The control (normal) theca cell preparations came from ovaries of fertile women with normal menstrual histories, menstrual cycles of 21-35 days, and no clinical signs of hyperandrogenism. Neither PCOS or normal subjects were receiving hormonal medications at the time of surgery. Indications for surgery were dysfunctional uterine bleeding, endometrial cancer, and pelvic pain. The passage conditions and split ratios for all normal and PCOS cells were identical. Experiments comparing PCOS and normal theca were performed utilizing 4th-passage (31-38 population doublings) theca cells isolated from size-matched follicles obtained from age-matched subjects.
Sera and growth factors were obtained from the following sources: FBS and DME/F12 were obtained from Irvine Scientific (Irvine, CA): horse serum was obtained from Life Technologies(Grand Island, NY); UltroSer G was from Reactifs IBF (Villeneuve-la-Garenne, France): other compounds were purchased from Sigma.
Transient transfections
Subconfluent theca cultures were transfected with reporter gene constructs using the calcium-phosphate method of Gram and Vander Eb (35) . One hour before transfection, the cells were transferred into DME high-glucose medium containing 20 mmol/L HEPES and 2% heatinactivated calf serum and moved to a 3% CO 2 , 95% ambient air, 37-C incubator. DNA/Ca 2 P0 4 solution containing 20 g of reporter plasmid and 5 g of pSV-␤gal/100-mm dish in HEPES phosphate buffer was added to the media. After incubation for 6 h, cells were transferred into 2% heat-inactivated calf serum in DME containing 20 mm HEPES and treated as described. Cells were harvested 24 -72 h after forskolin treatment using trypsin/EDTA, pelleted, and resuspended in 250 mmol/L Tris-HCL (pH 7.9) for chloramphenicol acetyltransferase (CAT) assays, and reporter lysis buffer for luciferase assays. The initial characterization of CYP17 and StAR reporter constructs was performed in theca cells propagated from several different PCOS patients, to facilitate analysis. Transfections were performed in triplicate, at least three times in theca cells isolated from various individual patients, using reporter plasmid isolated from several different plasmid preparations. Calf serum was obtained from Atlanta Biologicals (Atlanta, GA); other compounds were from Sigma.
CAT and luciferase assays
CAT activity was determined using the 3 H-chloramphenicol method (36), employing preferential extraction of acetylated chloramphenical with mixed xylenes. Luciferase assays were performed using the Luciferase assay system from Promega Corp. (Madison, Wisconsin). ␤-galactosidase (␤-gal) activity was determined by Galacton-Light Plus chemiluminescent assay from Tropix (Bedford, MA),and used to normalize CAT and luciferase activities. Chemiluminescence was measured with a Monolight 3010 Luminometer from Analytical Luminescence Laboratory (San Diego, CA). To control for transfection efficiency, relative CAT or luciferase activity was calculated by dividing the observed reporter activity by the corresponding ␤-gal activity.
Plasmids and construction of CYP17 promoter reporter constructs
The 5Ј flanking sequence of CYP17 was generously provided by Michael Waterman (Vanderbilt University, Nashville, TN). Reporter gene plasmids containing sequentially smaller fragments of the 5Ј flanking region of the human CYP17 gene were constructed using existing restriction sites. Ϫ1800/ϩ44 (NcoI/NaeI) Ϫ750/ϩ44 (NaeI/NaeI), Ϫ235/ϩ44 bp (SacI/NaeI), and Ϫ109/ϩ44 bp (SacI/NaeI) fragments of the CYP17 promoter were isolated and subcloned into the CAT reporter plasmid, PQrCAT (37) , to produce Ϫ1800, Ϫ750, Ϫ235, and Ϫ109 CYP17/CAT. The Ϫ235/ϩ44 bp (SacI/NaeI) fragment of the CYP17 promoter was also subcloned into the luciferase vector pGL3 basic (Promega Corp.), to produce Ϫ235 CYP17/LUC.
The human StAR promoter luciferase constructs have been previously described (31) (32) . The SF-1 expression plasmid, generously provided by Keith Parker (University of Texas Southwestern University, Dallas, TX), contains the full-length cDNA encoding mouse SF-1 in pCMV5. The ␤-gal control vector, pSV-bgal, was obtained from Promega Corp.
Statistical analysis
Each experiment was performed using triplicate dishes. After combining the results from individual patients, unpaired two-tailed t tests were performed using StatView 5.0 from SAS Institute, Inc. (Cary, NC).
Results
CYP17 promoter activity in human theca cells
A series of promoter constructs containing successive truncations of the 5Ј flanking sequence of the human CYP17 gene were generated (Fig. 1A) . Ϫ1800, Ϫ750, Ϫ235, and Ϫ109 CYP17 CAT reporter vectors (20 g/dish) were transiently transfected into human theca cells isolated from PCOS patients in the presence or absence of a pCMV5 expression vector (SF-1pCMV5) expressing mouse SF-1 (1 g/dish). In the absence of cotransfected SF-1 (Fig. 1B) , CAT activity was barely detectable after transfection of the Ϫ1800, Ϫ750, Ϫ235, and Ϫ109 CYP17 reporter constructs, under both control and forskolin-stimulated conditions. Cotransfection with SF-1 increased basal Ϫ1800 and Ϫ750 CYP17 reporter activity approximately 8-fold, and Ϫ235 CYP17 reporter activity approximately 4-fold over baseline values; whereas forskolinstimulated Ϫ1800, Ϫ750 CYP17, and Ϫ235 CYP17 reporter activity was increased approximately 22, approximately 20, and approximately 15-fold, respectively, over baseline levels. Forskolin-stimulated Ϫ1800, Ϫ750, and Ϫ235 CYP17 reporter activities were increased approximately 2-to 3-fold above basal values, in the presence of cotransfected SF-1. In contrast, after cotransfection with SF-1, Ϫ109 CYP17 reporter activity was not increased above baseline values in the presence or absence of forskolin. Forskolin-stimulated CYP17 reporter activity was found to be maximal after cotransfection with 1 g/dish of SF-1 expression plasmid (data not shown). To control for possible vector-specific interactions, these observations were confirmed after transfection of theca cells with a series of luciferase (pGL3) reporter constructs containing successive truncations of Ϫ750/ϩ44 of the CYP17 promoter (data not shown).
The time course of Ϫ1800 and Ϫ235 CYP17 reporter activity was examined with cotransfected SF-1. PCOS theca cells were transfected with 20 g/dish Ϫ1800 and Ϫ235 CYP17 reporter vector and 1 g/dish of SF-1 expression plasmid. After 24, 48, and 72 h of treatment, in the presence or absence of 20 mol/L forskolin (F), the cells were harvested and CAT activity quantitated. At time points beyond 72 h, cell viability was decreased, limiting accurate assessment of CAT activity. As shown in Fig. 2 , under basal conditions, reporter activity was only marginally increased after transfection of Ϫ1800 or Ϫ235 CYP17/CAT over 72 h. After 24 h of forskolin treatment, Ϫ1800 and Ϫ235 CYP17 reporter activity was unchanged. Forskolin-stimulated Ϫ1800 CYP17 reporter activity was increased approximately 2-fold at 48 h and approximately 7-fold at 72 h, over respective control values. Ϫ235 CYP17 reporter activity was also increased approximately 2-fold at 48 h and increased 4-fold at 72 h, over respective control values, in response to forskolin. As shown in Fig. 2 , 72 h of treatment is required for maximal induction of forskolin-stimulated Ϫ1800 and Ϫ 235 CYP17 reporter activity. These data are in agreement with the time course of forskolin-stimulated CYP17 mRNA accumulation in passaged human theca cells (data not shown), showing that cAMP-dependent increases in CYP17 mRNA require a lag time of 24 -48 h.
StAR promoter activity in human theca cells
Transient transfection studies were performed using a series of human StAR constructs (31, 32) containing deletion mutants of the 5Ј flanking sequence of the human StAR gene fused to the luciferase reporter pGL2 (Fig. 3A) . Ϫ1300, Ϫ885, Ϫ150, and Ϫ43 StAR reporter vectors (20 g/dish) were transiently transfected into human theca cells isolated from PCOS patients in the presence or absence of SF-1pCMV5 (1 g/dish) (Fig. 3B) . After 72 h of treatment, in the absence or presence of 20 mol/L forskolin, the cells were harvested and luciferase activity quantitated. As shown in Fig. 3B , in the absence of cotransfected SF-1, forskolin-stimulated Ϫ1300, Ϫ885, and Ϫ150 StAR reporter activity was increased approximately 3-fold over basal conditions. In contrast, there was no increase in forskolin-stimulated Ϫ43 StAR reporter activity in the absence of SF-1. Upon cotransfection of SF-1, Ϫ1300, Ϫ850, and Ϫ150 StAR reporter activity increased 3-fold above values observed in the absence of SF-1 cotransfection, under control conditions. Forskolin-stimulated Ϫ1300 StAR reporter activity increased 6-fold, whereas Ϫ885 and Ϫ150 StAR reporter activity increased 3-fold, and Ϫ43 StAR reporter activity, which was very low, increased 2-fold over basal values after cotransfection with SF-1. The lack of a requirement for SF-1 cotransfection for detection of StAR reporter activity in human theca cells is in agreement with our previous observations in human granulosa cells transfected under identical conditions (31) .
Comparison of CYP17 reporter activity in normal and PCOS theca cells
To determine whether increased steady-state CYP17 mRNA accumulation in PCOS theca cells is associated with increased transcriptional activation of the CYP17 gene, basal and forskolin-stimulated CYP17 reporter activity was examined in theca cells isolated from three normal and three PCOS patients. Ϫ1800, Ϫ750, Ϫ235, and Ϫ109 CYP17 CAT reporter constructs (Fig. 1A) were transiently transfected into normal and PCOS theca cells in the presence of SF-1pCMV5. In contrast to the data presented in Figs. 1-3 , reporter activity is presented as fold increase above values for the empty PQrCAT reporter vector, to control for patient-to-patient variation in transfection efficiency. As shown in Fig. 4 , the fold increase in both basal and forskolin-stimulated CAT activities of Ϫ1800, Ϫ750, and Ϫ235 CYP17 reporter constructs was greater in PCOS theca cells than in normal theca cells. The basal reporter activities in PCOS theca cells were, on average, approximately 4-fold greater than respective reporter activities in normal theca cells (P Ͻ .001). The fold increase in forskolin-stimulated reporter activity in PCOS theca cells was approximately 10-times greater than respective reporter activities in normal theca cells (P Ͻ .001). In the absence of cotransfected SF-1, CYP17 reporter activity was not detectable in normal or PCOS theca cells.
To increase assay sensitivity and confirm that differences in CYP17 reporter activity were promoter-specific and not a consequence of vector background, we examined the promoter activity of a luciferase reporter construct (pGL3) containing Ϫ235/ϩ44 of the CYP17 gene (Ϫ235 CYP17/LUC). Theca cells from three normal and three PCOS patients were transfected with Ϫ235 CYP17/LUC in the presence of SF-1pCMV5. As shown in Fig. 5 , forskolin-stimulated Ϫ235 CYP17/LUC reporter activity increased more than 2-fold above basal values in both normal and PCOS theca cells (P Ͻ .01). As with the CYP17/ CAT reporter constructs, CYP17/LUC reporter activity was not detectable in normal or PCOS theca cells in the absence of cotransfected SF-1. The fold-increase in basal and forskolinstimulated luciferase activity in PCOS theca cells was approximately 3-fold greater than respective activities in normal theca cells (P Ͻ .01). These data are in agreement with those presented in Fig. 4 , and they confirm that increased CYP17 promoter activity is increased in PCOS. These data support the notion that basal and forskolin-stimulated CYP17 gene transcription are increased in PCOS theca cells. Moreover, the observed increases in basal and forskolin-stimulated CYP17 reporter activities are in agreement with our previous report of increased CYP17 enzyme activity/cell and increased steady-state CYP17 mRNA accumulation in propagated PCOS theca cells (5) .
Comparison of 3xCRE reporter activity in normal and PCOS theca cells
To determine whether the cAMP signal transduction pathway is altered in PCOS theca cells, we transiently transfected normal and PCOS theca cells with a vector containing three copies of a cAMP-response element (TGACGTCA) (38) fused to a luciferase reporter, 3xCREpGL3 (39) . Theca cells, isolated from three normal and three PCOS patients, were transiently transfected with 3xCREpGL3 (20 g/dish) and cultured, in the absence or presence of 20 mol/L forskolin, for 24 h. To control for patient-to-patient variation in transfection efficiency, reporter activity is presented as fold increase above values for the empty pGL3 reporter vector. As shown in Fig.  6 , the fold-increase in basal and forskolin-stimulated 3xCREpGL3 reporter activities were not significantly different in PCOS theca cells, as compared with normal theca cells. In normal and PCOS theca cells, 3xCREpGL3 reporter activity increased approximately 4-fold above basal values, in response to F treatment (P Ͻ .01). These data are in agreement with previous observations that the ED 50 for forskolin-stimulated CYP17 activity/expression is identical in normal and PCOS theca cells (5) . These data also suggest that adenylate cyclase/cAMP levels and the signal transduction cascades mediating cAMP stimulation of gene transcription are not altered in PCOS theca cells.
Comparison of StAR reporter activity in normal and PCOS theca cells
To determine whether transcriptional regulation of the StAR promoter is altered in PCOS theca cells as compared with normal theca cells, theca cells isolated from three in- dividual and three PCOS patients were transiently transfected with the Ϫ885 StAR luciferase construct (20 g/dish) and cultured, in the absence or presence of 20 mol/L forskolin, for 72 h. To control for patient-to-patient variation in transfection efficiency, reporter activity is presented as foldincrease above values for the empty pGL3 reporter vector. In both normal and PCOS theca cells, Ϫ885 StAR reporter activity increased approximately 3-fold above basal values, in response to forskolin treatment, with and without SF-1 cotransfection (P Ͻ .01). Although cotransfection with SF-1 proportionally increased basal and forskolin-stimulated StAR reporter activity in both cell types (Fig. 7) , the foldincreases in basal and forskolin-stimulated StAR luciferase activities were not significantly different in PCOS theca cells, as compared with normal theca cells. These data are consistent with our previous Northern blot data demonstrating the lack of a significant difference in basal or forskolin-stimulated StAR mRNA accumulation in normal and PCOS theca cells (5) .
Discussion
The ability to propagate human theca cells for successive population doublings has allowed us to begin to examine the transcriptional regulation of the CYP17 and StAR gene in normal and PCOS theca cells. Our goal was to determine whether enhanced basal and forskolin-stimulated CYP17 mRNA levels, (CYP17) activity, and androgen production in PCOS theca cells results from increased transcriptional activation of the CYP17 gene. Because basal and forskolindependent StAR mRNA accumulation was previously found not to be different in normal and PCOS theca cells, we also examined the transcriptional regulation of the StAR gene. By comparing CYP17 and StAR promoter activities in normal and PCOS cells, we hoped to obtain information that could be used to extend our current knowledge of the molecular and cellular basis for increased androgen production in PCOS.
In this report, theca cell preparations that had previously been characterized for their steroidogenic potential (5) were transfected with DNA plasmids containing the 5Ј flanking sequence of the human CYP17 or StAR genes fused to reporters. In theca cells transfected with a series of CYP17 reporter constructs, cotransfection of SF-1 was required for the detection of both basal and stimulated promoter activity. Both basal and forskolin-stimulated Ϫ750 and Ϫ235 CYP17 reporter activities were increased after cotransfection with SF-1. In contrast, Ϫ109 CYP17 reporter activity was not increased in response to forskolin or SF-1. These data indicate that the elements involved in cAMP-dependent regulation of the CYP17 gene in human theca cells lie within Ϫ750/Ϫ109 bp of the transcription start site, with the primary element(s) lying between Ϫ235/Ϫ109 bp. The relative increases in SF-1-dependent CYP17 reporter activity is consistent with the number of putative SF-1 response elements in the 5Ј flanking sequence of the CYP17 gene (27) . The Ϫ750 CYP17 construct contains more SF-1 consensus binding motifs than the Ϫ235 CYP17 construct, and exhibits greater activity. Also, the Ϫ235 CYP17 construct contains SF-1 binding motifs not present in the Ϫ109/CAT vector.
It is noteworthy that the region of the CYP17 promoter that confers cAMP inducibility in theca cells (Ϫ235/Ϫ109) is distinct from that previously reported for regulation of the human CYP17 gene in human H295 adrenal cells (23, 40) . In human adrenal NCIH295 cells, the regulatory sequences involved in cAMP-dependent expression of CYP17 reporter constructs lie within the first Ϫ63 bp upstream of the start site of transcription (23) . Moreover, the DNA sequences that confer cAMP-inducibility of the CYP17 gene in human theca cells are evidently different from elements that seem to be their functional equivalents in human NCI-H295 adrenal cells (23) , mouse adrenal Y1 cells (19, 41) , and mouse leydig MA10 cells (22, 23, 41) . In addition, the Ϫ235/Ϫ109 CYP17 sequences we found necessary for cAMP-regulation in human theca cells have no sequence homology to the Ϫ80/Ϫ40 region of the bovine CYP17 gene ,which was shown to be necessary for cAMP-regulation in bovine theca cells (21) . Thus, our data are consistent with those of Rodriguez et al. (23) and confirm that the promoter elements that confer transcriptional activation of the CYP17 gene are not only tissue-specific but are species-specific as well.
SF-1-and cAMP-dependent regulation of human StAR gene expression has been examined in a variety of cell systems (24, 31, 32) . Transient transfection studies of StAR reporter constructs in human granulosa cells identified several SF-1 binding sites involved in basal, as well as cAMPdependent, regulation (31) . However, the transcriptional regulation of the human StAR promoter has never been examined in human theca cells. In this report, we established that, in human theca cells Ϫ1300, Ϫ885, and Ϫ150, StAR reporter activity is increased in response to forskolin treatment in the absence of SF-1 cotransfection. Cotransfection of SF-1 augmented both basal and forskolin-stimulated StAR promoter function. In transient transfections of human granulosalutein cells in long-term culture, SF-1 cotransfection was not required for StAR reporter activation. The reduction in forskolin-stimulated Ϫ885 StAR reporter activity, as compared with Ϫ1300 StAR reporter activity we observed in human theca cells, may be attributed to the deletion of an SF-1 binding site at Ϫ926 to Ϫ918, which has been shown to be required for maximal StAR reporter activity in human granulosa-lutein cells (31, 32) . Similarly, the deletion of a SF-1 binding site at Ϫ105 to Ϫ95 (31, 32) may also explain the reduction in forskolin-stimulated Ϫ43 StAR reporter activity, as compared with the activity of the Ϫ150 StAR construct.
The finding that SF-1 cotransfection is required for detection of CYP17 promoter activity, but not for StAR promoter activity, raises the possibility that the mechanism by which CYP17 gene transcription is regulated by SF-1 in theca cells is distinct from that controlling StAR gene transcription. We initially believed that the requirement for SF-1 cotransfection for expression of our CYP17 reporter constructs resulted from insufficient endogenous SF-1 under conditions where reporter plasmid DNA was in excess. However, the fact that human StAR reporter activity, which has been previously shown to require functional SF-1 response elements (24, 31, 32) does not require SF-1 cotransfection under identical conditions, indicates that endogenous theca cell SF-1 concentrations are sufficient to drive StAR gene transcription. Similarly, our preliminary experiments indicate that endogenous SF-1 levels are sufficient for the expression of CYP11A promoter activity in human theca cells. These data demonstrate that the requirement for SF-1 cotransfection in the examination of basal and cAMP-stimulated CYP17 reporter activity is promoter-specific and is not an artifact of our culture or transfection conditions. Given that the human CYP17 gene has numerous SF-1 response elements in its 5Ј flanking sequence (27) , it is conceivable that CYP17 promoter demands greater concentrations of SF-1 than the human CYP11A or StAR promoters. It is also possible that the intracellular mechanism(s) involved in SF-1-dependent activation of the CYP17 gene involves additional transcription factors that may not affect CYP11A or StAR gene transcription. For instance, the orphan nuclear receptor, COUP-TF (42) , has been shown to compete for overlapping binding sites on both the human and bovine CYP17 promoters (40, 43, 44) . It has been reported that cAMP-dependent transactivation of the mouse and bovine CYP17 promoter constructs requires SF-1-dependent displacement of COUP from the CYP17 reporter (43, 44) . Hence, it is possible that SF-1 cotransfection in theca cells is required for displacement of COUP from the CYP17 reporter. In contrast, the mechanism for increased StAR and CYP11A expression may not involve displacement of COUP, and therefore would require less SF-1 for transactivation. Alternatively, it is possible that cAMP-dependent StAR and CYP11A promoter regulation involves additional transcription factors (or cofactors) that act cooperatively with endogenous SF-1, thereby negating the requirement for SF-1.
Transfection analysis of CYP17 promoter constructs in normal and PCOS theca cells has confirmed that increased steady-state levels of CYP17 mRNA in PCOS theca cells results, at least in part, from increased CYP17 gene transcription. Both basal and forskolin-stimulated CYP17 reporter activity is markedly increased in PCOS theca cells. The observed increases in basal and forskolin-stimulated CYP17 reporter activities are in agreement with our previous report of increased CYP17 enzyme activity/cell and increased steady-state CYP17 mRNA accumulation in propagated PCOS theca cells (5) . In contrast, Ϫ885 StAR promoter activity was not different in normal and PCOS theca cells. These data are also in agreement with previous Northern blot data showing that basal and forskolin-stimulated StAR mRNA accumulation are not significantly different in normal and PCOS theca cells (5) .
Increased CYP17 reporter activity in PCOS does not seem to result from differences in forskolin-stimulated adenylate cyclase activity in normal and PCOS theca cells, because there were no differences in reporter activity in normal and PCOS theca cells transfected with a plasmid containing three classical cAMP-response elements (3xCRE) or the Ϫ885 StAR reporter construct. Similarly, increased CYP17 mRNA accumulation does not seem to result from increased adenylate cyclase activity, because StAR mRNA accumulation is unaffected. Furthermore, although progesterone and 17␣-hydroxyprogesterone production are markedly increased in PCOS theca cells, the ED 50 for forskolin-stimulated production of these steroids is identical in normal and PCOS theca cells (5) .
In conclusion, our data suggest that dysregulation of the processes involved in CYP17 transcription in PCOS theca cells may, in part, account for increased ovarian androgen production in patients with PCOS. Examination of the cisregulatory sequences and trans-acting factors involved in cAMP-and SF-1-dependent regulation of the CYP17 gene in normal and PCOS theca cells will further our understanding of the molecular mechanisms underlying increased CYP17 transcription in PCOS. Furthermore, identification of the signal transduction pathways involved in increased CYP17 expression, and overall androgen production in PCOS theca cells, may provide valuable information that can be applied
